External links
- Andrea Califano publications indexed by Google Scholar
| International | |
|---|---|
| National | |
| Academics | |
| People | |
| Other | |
Andrea Califano | |
|---|---|
| Education | University of Florence |
| Awards | Member of the National Academy of Sciences (since 2018) Fellow of the AAAS (since 2015) Fellow of the ISCB (since 2017) Fellow of the AACR (since 2024) Fellow of the IEEE (since 1997) |
| Scientific career | |
| Fields | Systems biology, Computational biology, Cancer genetics |
| Institutions | Chan Zuckerberg Biohub Columbia University Irving Medical Center |
| Website | califano |
Andrea Califano is a systems biologist. He is the Clyde and Helen Wu Professor of Chemical and Systems Biology at Columbia University Irving Medical Center, where he also holds appointments in the Departments of Biochemistry and Molecular Biophysics, Biomedical Informatics, and Medicine. Califano serves as the president of the Chan Zuckerberg Biohub New York.
Califano was born in Naples, Italy.[ citation needed ] He earned a Ph.D. in physics from the University of Florence in 1986 and completed postdoctoral training in optics at the Istituto Nazionale di Ottica in Florence, information mechanics at the Massachusetts Institute of Technology, and computational biology at the IBM T.J. Watson Research Center. [1]
Califano began his career at IBM, where he established the company’s first Computational Biology group in 1990 and later became program director of the IBM Computational Biology Center in 1997. [2] In 2000, he co-founded First Genetic Trust, a pharmacogenomics company focused on human polymorphisms and drug response. [3]
He joined Columbia University in 2003 as Professor of Biomedical Informatics and was later named the Clyde and Helen Wu Professor of Chemical and Systems Biology. He founded the Department of Systems Biology in 2013, serving as its first chair until 2023. Califano also held leadership positions at the Herbert Irving Comprehensive Cancer Center, including Associate Director for Bioinformatics from 2007 to 2019 and Co-Leader of the Cancer Regulatory Network and Precision Oncology and Systems Biology Programs. [4]
In 2010, Califano co-founded Therasis, a systems biology-based company focused on novel cancer treatments, [5] and in 2015 co-founded DarwinHealth, a biotechnology company leveraging proprietary algorithms developed in his laboratory for precision oncology. [6]
Califano is a contributor to website EXPeditions. [7]
In 2023, he became President of the Chan Zuckerberg Biohub New York, an initiative dedicated to re-engineering the human immune system to detect and prevent cancer and neurodegenerative diseases. [8]
Califano is known for pioneering the use of mammalian regulatory networks in modeling cancer-related phenotypes and identifying master regulator proteins that control cellular states. He introduced the OncoTecture hypothesis and formulated the Information Canalization Theory, which explains how conserved regulatory modules maintain homeostasis in both normal and diseased cells. [9]
His laboratory developed several influential computational tools, including:
ARACNe – an algorithm for reconstructing gene regulatory networks using information theory. [10] [11]
VIPER – a framework for inferring protein activity from gene expression data to identify master regulators. [12]
OncoTarget and OncoTreat – mRNA-based clinical decision tools for predicting optimal cancer therapies, both approved under CLIA by the New York and California Departments of Health. [13]
These algorithms have been cited extensively and have been applied in more than ten clinical trials in precision oncology. Califano’s group has mentored over 120 graduate students and postdoctoral researchers.
Califano’s work has shown that cancer cell transcriptional states are maintained by small sets of autoregulated proteins known as master regulators, which form tumor checkpoint modules. These modules integrate the effects of numerous genetic alterations to produce stable cell phenotypes. Targeting these master regulators can reprogram or eliminate tumor cells, providing new therapeutic avenues beyond traditional mutation-driven approaches. [14]
Califano serves as a scientific editor for Cancer Discovery , [15] Cell Systems , and Science Signaling . He has served on advisory boards for the National Cancer Institute, [16] St. Jude Children's Research Hospital, Koch Institute for Integrative Cancer Research, [17] and Thermo Fisher Scientific. [18]
| International | |
|---|---|
| National | |
| Academics | |
| People | |
| Other | |
